2024 Eczema Treatment Roundup

We’ve had an exciting year for eczema medications. Since our last treatment roundup in December 2023, the Food and Drug Administration (FDA) approved four new treatments for eczema in 2024. There are also many promising new therapies rounding the corner to FDA review in 2025.

New eczema treatments in 2024

• A new topical cream. Approved by the FDA in July 2024, Zoryve (roflumilast cream 0.15%) is a PDE4 inhibitor topical cream developed by Arcutis Biotherapeutics for the treatment of mild to moderate atopic dermatitis in adults and children ages 6 years and older. Zoryve was previously approved as a foam (0.3%) for the treatment of seborrheic dermatitis in patients 9 years of age and older. Find answers to frequently asked questions about Zoryve here.
• A new biologic. Approved by the FDA in September 2024, Ebglyss (lebrikizumab-lbkz) is a IL-13 inhibitor biologic from manufacturer Eli Lilly and Company for the treatment of moderate-to-severe atopic dermatitis in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg). Find answers to frequently asked questions about Ebglyss here.
• A new biologic. Approved by the FDA in December 2024, Nemluvio (nemolizumab-ilto) is an IL-31 inhibitor biologic developed by Galderma for people ages 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI), whose disease is not adequately controlled with topical prescription therapies. Find answers to frequently asked questions about Nemluvio here.
• A new nonsteroidal topical. Approved by the FDA in December 2024, Vtama (tapinarof) cream (1%) is an aryl hydrocarbon receptor agonist and nonsteroidal topical cream from manufacturer Dermavant, an Organon company, for the treatment of atopic dermatitis in adults and children 2 years of age and older. Find answers to frequently asked questions about Vtama here.

What to expect in 2025

• The first prescription treatment for chronic hand eczema. The FDA has accepted a filing for delgocitinib cream 20 mg/g (2%) by LEO Pharma Inc. for the treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Delgocitnib is a topical pan-JAK inhibitor.  

Stay in the know

Stay up to date on the latest eczema therapies by visiting NationalEczema.org/new-treatments.